Jill Blackburn, a pediatric MS mom, founded the Pediatric Multiple Sclerosis Alliance to help other families of kids with the ...

Updates in relapsing-remitting MS from ECTRIMS 2025 examine lifestyle interventions, anti-CD20 therapies, efficacy of ...

New clinical trial data show children with MS may benefit as much from treatment with Ocrevus as Gilenya – and for some outcomes, more.

Please provide your email address to receive an email when new articles are posted on . Risk of treatment discontinuation at 2 years was six times higher with moderately effective therapies. Highly ...

Recent research has shed new light on multiple sclerosis (MS) in children, who make up about 3% to 5% of the MS population. At one time, children were thought to not experience disability due to their ...

Brenda Banwell, MD, Chief, Division of Neurology, Professor of Neurology, Perelman School of Medicine at the University of Pennsylvania, said that there are 3 areas of treatment associated with ...

The Jacobs Neurological Institute at UB has received a $1.8 million, five-year grant from the National Multiple Sclerosis Society to establish at Women and Children's Hospital of Buffalo one of six ...

Early treatment of pediatric-onset relapsing-remitting multiple sclerosis (MS) with high-efficacy therapy (HET) is associated with substantially slower disability progression than treatment with ...

“For the first time, we have an FDA-approved treatment specifically for children and adolescents with multiple sclerosis,” explains Billy Dunn, M.D., director of the Division of Neurology Products in ...

BUFFALO, N.Y. -- The Jacobs Neurological Institute of the University at Buffalo has received a $1.8 million, five-year grant from the National Multiple Sclerosis Society to establish at Women & ...

University of Alabama at Birmingham (UAB) School of Nursing Instructor Yolanda Wheeler, MSN, CRNP, CPNP-AC, wants to know how Multiple Sclerosis (MS) impacts decision-making in children. Using a ...

While diagnostic criteria for typical multiple sclerosis (MS) perform well in people ages 18 to 50, differential diagnoses in pediatric-onset MS and late-onset MS require specific considerations.